STAT+: Medicare still won’t say how much covering obesity drugs will cost

Medicare will cover Wegovy and Zepbound for weight loss starting July 2024 at $50/month for beneficiaries, but has not disclosed the cost to taxpayers. The temporary 'GLP-1 Bridge' program, running until December 2027, bypasses federal law and shifts most costs to taxpayers. The Trump administration initially planned coverage through Medicare Advantage plans, but insurers opposed due to high costs.